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Summary
Background Co-trimoxazole prophylaxis reduces mortality among HIV-infected children, but efficacy in HIV-exposed 
but uninfected (HEU) children in a non-malarial, low-breastfeeding setting with a low risk of mother-to-child 
transmission of HIV is unclear.
Methods HEU children in Botswana were randomly assigned to receive co-trimoxazole (100 mg/20 mg once daily until 
age 6 months and 200 mg/40 mg once daily thereafter) or placebo from age 14–34 days to age 15 months. Mothers 
chose whether to breastfeed or formula feed their children. Breastfed children were randomly assigned to breastfeeding 
for 6 months (Botswana guidelines) or 12 months (WHO guidelines). The primary outcome, analysed by a modified 
intention-to-treat approach, was cumulative child mortality from treatment assignment to age 18 months. We also 
assessed HIV-free survival by duration of breastfeeding. This trial is registered with ClinicalTrials.gov, 
number NCT01229761.
Findings From June 7, 2011, to April 2, 2015, 2848 HEU children were randomly assigned to receive co-trimoxazole 
(n=1423) or placebo (n=1425). The data and safety monitoring board stopped the study early because of a low likelihood 
of benefit with co-trimoxazole. Only 153 (5%) children were lost to follow-up (76 in the co-trimoxazole group and 77 in 
the placebo group), and 2053 (72%) received treatment continuously to age 15 months, death, or study closure. 
Mortality after the start of study treatment was similar in the two study groups: 30 children died in the co-trimoxazole 
group, compared with 34 in the placebo group (estimated mortality at 18 months 2·4% vs 2·6%; difference –0·2%, 
95% CI –1·5 to 1·0, p=0·70). We saw no difference in hospital admissions between groups (12·5% in the co-
trimoxazole group vs 17·4% in the placebo group, p=0·19) or grade 3–4 clinical adverse events (16·5% vs 18·4%, 
p=0·18). Grade 3–4 anaemia did not differ between groups (8·1% vs 8·3%, p=0·93), but grade 3–4 neutropenia was 
more frequent in the co-trimoxazole group than in the placebo group (8·1% vs 5·8%, p=0·03). More co-trimoxazole 
resistance in commensal Escherichia coli isolated from stool samples was seen in children aged 3 or 6 months in the 
co-trimoxazole group than in the placebo group (p=0·001 and p=0·01, respectively). 572 (20%) children were 
breastfed. HIV infection and mortality did not differ significantly by duration of breastfeeding (3·9% for 6 months vs 
1·9% for 12 months, p=0·21).
Interpretation Prophylactic co-trimoxazole seems to offer no survival benefit among HEU children in non-malarial, 
low-breastfeeding areas with a low risk of mother-to-child transmission of HIV.
Funding US National Institutes of Health.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license. 
Introduction
Co-trimoxazole prophylaxis reduces mortality among 
HIV-infected children by preventing opportunistic 
infections, diarrhoeal and respiratory illnesses, and 
malaria, and use is recommended up to at least age 
5 years.1–5 WHO recommends that all HIV-exposed 
children receive co-trimoxazole until HIV infection has 
been ruled out and HIV exposure from breastmilk has 
ended.6,7 With improvements in availability of antiretroviral 
treatment (ART), however, mother-to-child HIV 
transmission has decreased, and in some areas the vast 
majority of HIV-exposed children now remain uninfected. 
The risks and benefits of co-trimoxazole prophylaxis in 
these children are unknown. A small randomised trial 
involving HIV-exposed but uninfected (HEU) infants in 
Uganda showed lower incidence of malaria among 
children who continued prophylactic co-trimoxazole to 
age 4 years than among those who stopped after 2 years of 
treatment.8 Reductions in the incidence of malaria 
associated with co-trimoxazole prophylaxis have been 
reported in several other studies.8–13 Observational data are 
conflicting for non-malarial health benefits of co-
trimoxazole in HEU children, with some studies showing 
no association between co-trimoxazole and common 
childhood illnesses, such as lower respiratory tract 
infections or diarrhoea,14 and other studies suggesting a 
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protective effect of co-trimoxazole.15 Although mortality 
among HEU children is higher than that among children 
not exposed to HIV,16–19 whether they would benefit from 
prophylactic co-trimoxazole needs to be assessed in 
randomised clinical trials in non-malarial settings.
We did a double-blinded, randomised, placebo-controlled 
trial to investigate whether co-trimoxazole would offer a 
survival benefit for HEU children in a non-malarial region 
of Botswana. This cohort also offered an opportunity to 
assess a potential relation between breastfeeding duration 
and child mortality.
Methods
Study design and participants
In this trial, known as the Mpepu Study (Mpepu means 
“to carry a baby on your back” in Setswana), we enrolled 
HIV-infected women and their children in southern 
Botswana, which is an area without malaria 
transmission. Participants were identified at either 
public antenatal clinics or maternity wards in Gaborone 
(a city), Molepolole (a village), and Lobatse (a town, 
included up to August, 2012). Women who were in at 
least week 26 of pregnancy through to 34 days post 
partum were eligible. Other maternal inclusion criteria 
were documented HIV-1-positive status, age 18 years or 
older, ability to provide written informed consent and 
attend the study clinic for follow-up, and Botswana 
citizenship. Exclusion criteria for randomisation of 
children included a previous positive HIV result on a 
qualitative DNA PCR test, any medical condition 
making survival to 18 months unlikely, clinical 
jaundice, known allergy to sulphonamide drugs or 
other contraindication to starting co-trimoxazole, and 
grade 4 asymptomatic or grade 3 symptomatic anaemia 
or neutropenia. Children with negative HIV DNA PCR 
results at birth who had positive results in blood 
samples taken at the time of randomisation were 
excluded from analyses.
Throughout the study period, Botswana feeding 
guidelines supported the provision of free formula but 
allowed for breastfeeding by mothers receiving ART. 
These guidelines differ from most other countries in 
Africa, which support breastfeeding in the setting of 
maternal ART or infant prophylaxis.20 Women who had 
not chosen a feeding method before enrolment in the 
study were provided with education on the risks and 
benefits of formula versus breastfeeding by study staff, 
from government-approved counselling information. 
Study staff also provided further information on the 
method selected (eg, safe formula preparation or exclusive 
breastfeeding followed by weaning over a 4-week period). 
Free maternal three-drug ART was available to all 
participating mothers during pregnancy and breastfeeding 
through the Botswana Government’s health system. All 
neonates received antiretroviral prophylaxis in the first 
4 weeks of life, regardless of feeding method. If a breast-
feeding mother was not taking ART for any reason, 
prophylactic nevirapine was provided to her child, dosed 
per WHO guidelines.21 From May, 2011 (maternal 
enrolment), to January, 2013, we followed the Botswana 
guidelines for prevention of mother-to-child transmission 
of HIV, which recommended single-dose nevirapine plus 
4 weeks of zidovudine for antiretroviral prophylaxis in 
neonates. After January, 2013, we amended the study 
protocol to allow earlier use of co-trimoxazole, and, 
therefore, neonatal prophylaxis was revised to 4 weeks of 
nevirapine alone to avoid potential haematological toxic 
effects associated with concurrent use of zidovudine and 
co-trimoxazole. Most children received zidovudine for a 
brief period even after January, 2013. 
Research in context
Evidence before this study
Co-trimoxazole prophylaxis reduces mortality among 
HIV-infected children, and is recommended by WHO for all 
children born to HIV-infected mothers until the child is 
confirmed not to be infected with HIV and the period of HIV 
infection risk has ended. With declines in mother-to-child 
transmission of HIV due to improved antiretroviral availability, 
most children born to HIV-infected mothers now remain 
uninfected. However, the risk of mortality is higher among 
HIV-exposed but uninfected (HEU) children than in 
HIV-unexposed children, and long-term co-trimoxazole 
prophylaxis in children has been considered as a potential 
intervention to mitigate this excess risk. The effects of 
co-trimoxazole prophylaxis on health outcomes of HEU 
children in non-malarial areas are unknown.
Added value of this study
We did a randomised trial to assess the use of prophylactic 
co-trimoxazole among HIV-exposed uninfected children in a 
non-malarial setting. We randomly assigned 2848 babies free 
from HIV infection born to HIV-infected women to receive 
co-trimoxazole or placebo from age 14–34 days up to age 
15 months. Only 20% of children were breastfed. Child mortality 
occurring between randomisation and age 18 months did not 
differ between the co-trimoxazole and placebo groups.
Implications of all the available evidence
Previous evidence showed that co-trimoxazole prophylaxis 
reduces morbidity and mortality in HIV-infected children, and 
lowered the incidence of malaria among HEU children residing 
in malarial settings. However, our study, which was done in a 
non-malarial region of Botswana with a well established 
programme for prevention of mother-to-child transmission, 
showed no clinical benefit in HEU children of HIV-infected 
mothers. These findings collectively suggest that in 
non-malarial settings with low HIV transmission rates and 
relatively low child mortality, prophylaxis with co-trimoxazole 
might not improve child health outcomes.
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The Botswana Government Health Research 
Development Committee and the Office for Human 
Research Administration, Harvard T H Chan School of 
Public Health, Boston, MA, USA, approved the study 
protocol and amendments. An independent data and 
safety monitoring board (DSMB) reviewed the safety and 
efficacy data approximately every 6 months and assessed 
futility. Participants signed written consent forms 
approved by the ethics review boards.
Randomisation and masking
The study data manager in Botswana electronically 
generated random allocation sequences. HEU children 
were randomly assigned 1:1 to receive either 100 mg/20 mg 
co-trimoxazole once daily until age 6 months and 
200 mg/40 mg co-trimoxazole once daily thereafter 
(standard WHO dosing at the time22) or placebo. Children 
were randomly assigned treatment in blocks of eight, 
stratified by study site. Before Jan 21, 2013, children were 
randomly assigned treatment when they were aged 
28–34 days. From this date onwards, in an effort to address 
early mortality, we extended the age full-term babies 
weighing more than 2500 g could be allocated treatment to 
14–34 days; age of allocation remained as 28–34 days in 
babies born before 37 weeks’ gestation or who weighed less 
than 2500 g at a visit between age 14 and 27 days. Children 
of breastfeeding mothers who gave consent were also 
randomly assigned to breastfeeding for 6 months (the 
recommended duration in Botswana) or 12 months (the 
duration recommended by WHO during the study period). 
We allocated these children by factorial randomisation to 
co-trimoxazole versus placebo and to 6 versus 12 months 
of breastfeeding (ie, into one of four possible groups).
Apart from the data manager, all study staff, investigators, 
and participants were unaware of treatment allocation. 
To mask treatment, co-trimoxazole and placebo were 
dispensed as syrup with similar colour, density, and taste, 
in brown opaque plastic bottles.
Procedures
Before treatment allocation, we did full blood and 
CD4 cell counts in enrolled women. HIV-1 RNA was 
quantified only in women enrolled up to Nov 6, 2012, due 
to cost constraints, with the automated COBAS 
Amplicor/AmpliPrep HIV-1 Monitor Test (version 1.5, 
Roche Molecular Systems, Branchburg, NJ, USA). 
Children were clinically assessed at birth, randomisation, 
ages 2 months and 3 months, and every 3 months 
thereafter until age 18 months. Peripheral blood was 
taken from all babies at the birth and random treatment 
assignment visits, and at ages 3, 6, 9, 12, and 15 months 
from breastfeeding children for HIV testing by qualitative 
PCR DNA assay with Amplicor HIV-1 testing (Roche 
Diagnostic Systems, Branchburg, NJ, USA). Full blood 
counts for children were done at the time of treatment 
assignment and ages 3, 6, and 15 months, and HIV 
ELISA was done at age 18 months. Children who had 
positive HIV tests at or after random treatment 
assignment were given active co-trimoxazole and ART 
provided by the Botswana Government, and were 
retained in the study follow-up and primary analysis.
Definitions
Maternal HIV infection status was established from 
documentation in health records of a positive HIV test 
or by in-study testing with ELISA, dual rapid enzyme 
immunoassay, or detectable HIV-1 RNA assay. HIV-
infected children were defined as having positive HIV 
DNA PCR results on two occasions (or one occasion 
followed by death before repeat testing). Preterm was 
defined as birth earlier than 37 weeks’ gestation, and low 
birthweight as less than 2500 g. Adherence to study drug 
was measured as the number of drug refills dispensed at 
study visits and by maternal or caregiver report at each 
clinic visit. For children who went off study treatment 
early due to non-attendance of study visits, we used the 
earlier of reported discontinuation or the first of 
consecutive missed visits, including the month 12 visit, 
as the imputed date of treatment discontinuation. 
Clinical adverse events and laboratory results were 
graded with the Division of AIDS Table for Grading the 
Severity of Adult and Pediatric Adverse Events, 
version 1.0.23 
Outcomes
The primary outcome was cumulative mortality up to 
age 18 months in children without HIV infection at 
treatment assignment. We had originally planned a 
second primary outcome of child HIV-free survival after 
6 months versus 12 months of breastfeeding, which had 
been based on the assumption that approximately 80% 
of infants would be breastfed. Owing to the much lower 
proportion (20%) of children being breastfed, however, 
we amended the protocol in January, 2013, and 
recategorised this outcome to be a secondary outcome. 
As a secondary composite clinical endpoint we assessed 
the occurrence of death, admission to hospital, or a 
grade 3 or 4 clinical adverse event. Other secondary 
clinical endpoints, analysed separately, were the 
cumulative incidence of admission to hospital, any 
grade 3–4 adverse events or grade 2 rash, grade 3–4 
anaemia, grade 3–4 neutropenia, and a composite of 
HIV infection or death at 18 months.
Co-trimoxazole resistance testing
From May, 2014, stool samples were collected from 
children, when possible, at the time of treatment 
assignment or at age 3 or 6 months. Samples were stored 
at –70°C before culture on MacConkey agar. Antibiotic 
susceptibility testing was done with the Kirby Bauer 
method on Mueller Hinton agar for 25 µg co-trimoxazole 
in samples that grew Escherichia coli. We used Clinical and 
Laboratory Standards Institute performance standards for 
disc diffusion to classify resistant isolates.24
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Statistical analysis
We calculated that 3016 children randomly assigned 
treatment would need to be retained in follow-up to 
provide 80% power to detect a 40% decrease in mortality 
from treatment assignment to age 18 months, from 
5·2% (based on mortality estimates from previous 
clinical trial data25) to 3·1%, with a two-sided type I error 
rate of 0·05. For children not known to have died, follow-
up was calculated from treatment assignment to the 
latest date during the study the child was known to be 
alive or exactly 18 months from the date of birth if they 
were known to be alive beyond that age. We used Kaplan-
Meier survival estimates to compare proportions of 
children alive at age 18 months in the co-trimoxazole and 
placebo groups, and used Greenwood’s formula to 
calculate the SE of the difference. We did analyses in a 
modified intention-to-treat population, from which we 
excluded infants randomly assigned treatment after 
having  negative DNA PCR results for HIV at birth and 
who later had positive DNA PCR results in blood samples 
taken at the time of treatment assignment.
For the secondary endpoints we analysed the 
differences (and SEs) in estimated proportions between 
groups at age 18 months, derived from Kaplan-Meier 
analysis. We used interval-censored survival methods26 to 
assess all endpoints for clinical adverse events, admission 
to hospital, and diarrhoea, because dates for some events 
were not collected (eg, diarrhoea between study visits).
We did additional exploratory analyses of mortality in 
children who did not miss any medication refills, with 
follow-up censored at the first missed visit or 
discontinuation of study treatment, whichever was 
earliest. We also assessed whether mortality was affected 
by different degrees of adherence (≥1 or ≥2 missed days 
of treatment). We compared bacterial resistance in the 
two study groups by Fisher’s exact test. We used Cox 
proportional hazards models separately adjusted for 
maternal and child baseline covariates to assess the effect 
of treatment on the primary endpoint, after checking that 
the proportional hazards assumption was satisfied. This 
trial is registered with ClinicalTrials.gov, number 
NCT01229761.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results
Between May 11, 2011, and April 2, 2015 we enrolled 
mothers, and between June 7, 2011, and April 2, 2015, 
babies were randomly assigned to treatment groups. 
Approximately 45 311 women gave birth at the maternity 
sites actively recruiting for the Mpepu Study, of whom 
10 752 (24%) had confirmed HIV infection. 6556 were 
approached for the study, and 3334 (51%) were enrolled 
(figure 1). Among the enrolled women, 506 had babies 
who were not randomly assigned treatment, of whom 
16 (<1%) tested positive for HIV before allocation 
(figure 1). 18 (<1%) babies had positive HIV results from 
blood samples drawn at the time of random assignment 
and were excluded from analyses per protocol. 2848 of 
the target 3016 children without HIV infection were 
randomly assigned to receive co-trimoxazole (n=1423) or 
placebo (n=1425). On April 2, 2015, accrual was stopped 
early because the DSMB judged that a benefit with co-
trimoxazole would be unlikely. Characteristics of mothers 
and children were well balanced across the two study 
groups at random assignment (table 1).
Loss-to-follow-up was low. The vital status of 2695 (95%) 
of 2848 children randomly assigned treatment was 
known at age 18 months or at study closure (figure 1). 
Data were censored for 1106 children (553 [39%] of 
1423 in the co-trimoxazole group and 553 [39%] of 1425 in 
the placebo group) before the 18-month visit, mainly 
because of study closure (953 [86%]). 2053 (72%) children 
Figure 1: Trial profile
*36 women had twins and one woman had triplets.
6556 HIV-positive women approached for study participation
3334 women enrolled
3222 women not enrolled
 1586 resided outside of study area
 261 not in gestational age or post-partum window
 198 not Botswana citizen
 70 age <18 years
 587 wanted to discuss with family
 143 woman or family member declined
 377 other reasons
2866 children born to 2828 women randomly assigned treatment*
1423 children assigned to receive co-trimoxazole
1347 vital status known at 18 months
76 lost to follow-up
1348 vital status known at 18 months
77 lost to follow-up
1425 children assigned to receive placebo
506 women had no children randomly assigned treatment
 16 children HIV positive before random assignment
 33 died
 150 lost to follow-up
 98 study closure
 209 other reasons
18 children HIV positive at random treatment
 assignment and excluded from analyses
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attended all study visits, and thus received all medication 
refills, up to age 15 months, death, or study closure. 
272 (10%) children missed one or more visits but were 
taking the study treatment at the time of the 15-month 
visit, death, or study closure. The time to discontinuation 
of study treatment did not differ significantly between 
groups (p=0·35). Nine children were taken off study 
treatment before age 15 months or study closure because 
of adverse events (four in the co-trimoxazole group: 
neutropenia n=2 and anaemia n=2; five in the placebo 
group: rash n=1, Stevens-Johnson syndrome n=1, 
hepatitis n=2, and anaemia n=1). Nine children 
discontinued treatment due to participant choice (five in 
the co-trimoxazole group and four in the placebo group) 
or a positive HIV test while taking the study treatment 
(one in the placebo group).
Adherence to the study treatment was similar in the 
two groups at all visits. Caregivers reported complete 
adherence in 1344 (65%) of the 2053 children who 
attended all study visits up to the earlier of age 15 months, 
death, or study closure (664 [64%] in the co-trimoxazole 
group and 680 [67%] in the placebo group). Thus, total 
adherence by both methods of assessment (no missed 
refill visits and no missed doses in caregiver reports) was 
47% among all children randomly assigned study 
treatment. 608 (43%) children in the co-trimoxazole 
group and 597 (42%) in the placebo group had either 
missed at least one refill visit or had a caregiver report of 
missing at least one dose, and 523 (37%) and 521 (37%), 
respectively, had missed at least one refill visit or had 
caregiver report of missing at least two doses.
64 children died between random assignment of 
treatment and age 18 months: 30 in the co-trimoxazole 
group (diarrhoeal disease n=17, pneumonia n=7, sepsis 
n=1, malnutrition n=1, other n=1, and unknown n=3) and 
34 in the placebo group (diarrheal disease n=17, 
pneumonia n=8, sepsis n=5, other n=2, and unknown 
n=2). No deaths were judged to be probably or definitely 
related to study treatment. Three deaths were thought to 
be possibly related to study treatment, of which one was in 
the co-trimoxazole group and was due to confirmed acute 
Co-trimoxazole 
group (n=1423)
Placebo group 
(n=1425)
Mothers*
Study site
Gaborone (city) 847 (60%) 842 (59%)
Molepolole (village) 470 (33%) 476 (33%)
Lobatse (town)† 106 (7%) 107 (8%)
Age at enrolment (years) 31 (26–35) 30 (26–34)
Education
None or primary 232 (16%) 229 (16%)
Secondary 1087 (76%) 1081 (76%)
Tertiary 104 (7%) 115 (8%)
Personal monthly income (US$)‡
Unsure 5 (<1%) 7 (<1%)
None 932 (65%) 932 (65%)
<70 54 (4%) 71 (5%)
71–140 141 (10%) 121 (8%)
141–710 265 (19%) 265 (19%)
>710 26 (2%) 29 (2%)
Electricity in the home 754 (53%) 776 (54%)
Enrolled antepartum 259 (18%) 273 (19%)
CD4 cell count at 
enrolment (cells per µL)
504 (367–674) 508 (353–687)
HIV-1 RNA concentration 
at enrolment 
(copies per mL)§
≤40 (≤40–1293) ≤40 (≤40–1038)
Receiving three-drug antiretroviral treatment before delivery
No 174 (12%) 181 (13%)
Yes 1173 (82%) 1173 (82%)
No antiretrovirals 
during pregnancy
76 (5%) 71 (5%)
(Table 1 continues in next column)
Co-trimoxazole 
group (n=1423)
Placebo group 
(n=1425)
(Continued from previous column)
Children
Gestational age (weeks) 39 (37–40) 39 (37–40)
Premature (>32 but 
≤37 weeks’ gestation)
426 (30%) 403 (28%)
Very premature 
(≤32 weeks’ gestation)
36 (3%) 52 (4%)
Birthweight (kg)
Median 2·97 (2·64–3·28) 2·90 (2·60–3·23)
Low (>1·5 but ≤2·5 kg) 254 (18%) 273 (19%)
Very low (≤1·5 kg) 6 (0%) 9 (1%)
Received single-dose 
nevirapine at delivery
1375 (97%) 1374 (96%)
Received zidovudine 
at delivery
1403 (99%) 1402 (98%)
Feeding method at random assignment
Formula 1136 (80%) 1140 (80%)
Breastfeeding 287 (20%) 285 (20%)
Duration not 
randomly assigned¶
1 (<1%) 2 (<1%)
Randomly assigned to 
6 months’ duration
142 (10%) 138 (10%)
Randomly assigned to 
12 months’ duration
144 (10%) 145 (10%)
Congenital abnormality 20 (1%) 22 (2%)
Age at random assignment (days)
Median (IQR) 28 (16–30) 28 (16–30)
14–27 587 (41%) 570 (40%)
28–34|| 836 (59%) 851 (60%)
Data are number (%) or median (IQR). *2811 women contributed data for 
2848 children (1412 in the co-trimoxazole group and 1399 in the placebo group). 
†Included in recruitment until August, 2012. ‡Converted from Botswana Pula 
with the average conversion rate for the study period. §In the first 1514 women 
enrolled in the study. ¶Three breastfed babies were mistakenly recorded as being 
formula fed, and were not randomly assigned a breastfeeding duration. ||Includes 
two babies assigned treatment at age 35–37 days.
Table 1: Characteristics of mothers of and children at random assignment
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gastroenteritis. The estimated cumulative proportions of 
deaths after treatment assignment and by age 18 months 
were 2·4% for co-trimoxazole and 2·6% for placebo 
(difference –0·2%, 95% CI –1·5 to 1·0, p=0·70; figure 2A). 
Similar results were found in the exploratory analyses of 
children with no missed medication refills, with estimated 
cumulative proportions of those dying up to and including 
age 18 months of 2·0% in the co-trimoxazole group and 
2·5% in the placebo group (difference –0·5% 95% CI 
–1·7 to 0·7, p=0·43). Mortality was not affected by missing 
any days of treatment (≥1 or ≥2 days; data not shown).
Among 2848 children randomly assigned treatment, 
362 had grade 3 or worse clinical adverse events and six 
children (three in each group) had grade 2 rash (table 2). 
The proportions of children who had at least one 
grade 3–4 adverse event, were admitted to hospital at 
least once, and who met the composite clinical endpoint 
of death, admission to hospital, or a grade 3–4 clinical 
adverse event did not differ between groups (table 2, 
figure 2B). Frequency was similar in the co-trimoxazole 
and placebo groups for pneumonia (2·5% vs 3·6%, 
p=0·33) and diarrhoea (10·3% vs 9·0%, p=0·26). No 
kernicterus was seen among children who started 
treatment at the earliest age (14–27 days). Laboratory data 
were available for 2510 (88%) of 2848 children randomly 
assigned treatment. 319 (13%) had at least one grade 3 or 
worse haematological abnormality. The frequency of 
grade 3–4 anaemia did not differ between groups, but 
that of grade 3–4 neutropenia was significantly higher in 
the co-trimoxazole group (table 2).
Of the 572 women who were breastfeeding at the time 
of treatment assignment, 569 (99%) were randomly 
assigned to breastfeed for 6 months (n=280) or 12 months 
(n=289). In the 6-month breastfeeding group, the median 
duration of breastfeeding was 6 months (IQR 6–6). 
234 (84%) children were weaned before they completed 
study follow-up, of whom 168 (72%) were breastfed for 
the assigned duration. In the 12-month breastfeeding 
group, the median duration of breastfeeding was 
8 months (IQR 5–12). 221 (76%) children were weaned 
before they completed study follow-up, of whom 73 (33%) 
were breastfed for the assigned duration. Among the 
babies randomly assigned to 12 months of breastfeeding, 
144 (65%) were weaned before 12 months and four (2%) 
after 12 months, and among those assigned to 6 months 
of breastfeeding, 57 (24%) were weaned before and nine 
(4%) after 6 months.
ELISA at age 18 months was available for 259 (45%) of 
572 breastfed children, and of the 313 without ELISA, 
299 (96%) had had an HIV PCR test done either after 
weaning or within 3 months of his or her last visit. Tests 
for the remaining 14 children were missing due to early 
study closure, loss to follow-up, or death. HIV infection 
was detected in five children after randomisation, two who 
were breastfed (one randomised to 6 months and one to 
12 months of breastfeeding, but who were both breastfed 
for 12 months before their first positive HIV test) and 
Figure 2: Cumulative proportions of deaths and of the composite endpoint of death, admission to hospital, 
and grade 3–4 clinical adverse events in children from baseline to the end of the study
(A) Deaths. (B) Composite clinical endpoint. 
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Difference (95% CI) p value
Primary outcome
Deaths 30 (2·4%) 34 (2·6%) –0·2% (–1·5 to 1·0) 0·70
Secondary outcomes
≥1 admissions to hospital 125 (12·5%) 143 (17·4%) –4·9% (–12·2 to 2·4) 0·19
≥1 grade 3–4 clinical adverse event and 
grade 2 rash
176 (16·5%) 192 (18·4%) –1·9% (–4·7 to 0·9) 0·18
Death, admission to hospital, or 
grade 3–4 clinical adverse events
212 (17·3%) 237 (19·6%) –2·2% (–5·2 to 0·7) 0·13
Grade 3–4 laboratory events
Anaemia 83 (8·1%) 81 (8·3%) –0·1% (–2·8 to 2·6) 0·93
Neutropenia 95 (8·1%) 68 (5·8%) –2·3% (–0·2 to 4·3) 0·03
Adverse events are graded with the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, 
version 1.0.23 *Percentages expressed as the estimated proportions at age 18 months.  
Table 2: Outcomes
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three children not reported to have been breastfed, who 
we took to have had either false-negative results at the 
time of random assignment or unreported breastfeeding. 
One of the children first tested positive at the 3-month 
visit, two at the 12-month visit, and two at the 18-month 
visit. All five children were alive at the final study visit.
The frequency of death and HIV infection did not 
differ by feeding method or breastfeeding duration 
(table 3). Additionally, we found no difference between 
the co-trimoxazole and placebo groups for mortality 
alone among children who were formula fed or breastfed 
or by feeding duration (data not shown), although the 
study was not powered to detect these interactions.
Resistance to co-trimoxazole was based on 206 E coli 
isolates grown from stool specimens. For children with 
samples collected at the time of treatment assignment, 
the proportions with co-trimoxazole-resistant E coli were 
similar in the co-trimoxazole and placebo groups 
(11 [65%] of 17 vs 17 [61%] of 28) at randomisation. For 
children with samples collected at 3 months or 6 months, 
however, the proportions with resistance were higher in 
the co-trimoxazole group (3 months, 37 [95%] of 39 vs 
19 [51%] of 37, p=0·001; 6 months, 32 [84%] of 38 vs 
27 [58%] of 47, p=0·01). 
Discussion
Prophylactic co-trimoxazole was not associated with any 
survival benefit in HEU children born to HIV-infected 
women in southern Botswana. Although mortality was low 
overall, we also found no difference by study group in the 
prespecified composite clinical endpoint of death, 
admission to hospital, and grade 3–4 clinical adverse 
events. Co-trimoxazole was generally well tolerated and 
was not associated with either anaemia or adverse clinical 
outcomes, but was associated with increased numbers of 
cases of grade 3–4 neutropenia. Bacterial co-trimoxazole 
resistance in commensal stool flora was greater in the co-
trimoxazole group than in the placebo group.
Our findings contrast with those from several other 
studies assessing HEU children. An observational study 
in Malawi reported a hazard ratio of 0·48 (p=0·03) for 
death among children who received prophylactic co-
trimoxazole,15 and various studies, mainly from malarial 
regions and all in Africa, have suggested a benefit with 
co-trimoxazole prophylaxis among HIV-affected and 
unaffected populations.5,8–13 All these studies were done 
in areas with high childhood mortality.
Several factors might have accounted for the lack of 
benefit we saw with prophylactic co-trimoxazole. Although 
previous trials have reported benefits with co-trimoxazole 
in the prevention of routine respiratory and diarrhoeal 
bacterial illnesses,1,2 including in settings with high 
prevalence of resistant pathogens,3,4 the main contribution 
of co-trimoxazole might be in preventing opportunistic 
infections (its intended purpose) in HIV-positive children. 
We were unable to determine the number of deaths 
attributable to standard bacterial pathogens as compared 
with opportunistic infections. The contribution of malaria 
to mortality in previous studies might have been 
underestimated, and the benefits from co-trimoxazole in 
those studies have been suggested to be due largely to 
reductions in malaria. For example, in a household study 
in Uganda, co-trimoxazole prophylaxis in an individual 
infected with HIV significantly reduced the frequency of 
malaria and deaths in the entire household.3 Other studies 
have shown reduced incidence of clinical malaria9,10,27,28 and 
parasite burden11,12 in people who have received co-
trimoxazole prophylaxis. Bacterial resistance to co-
trimoxazole is common throughout Africa,29–31 which 
might have further diminished the effect of co-trimoxazole 
on preventing death from standard diarrhoeal and 
respiratory pathogens. Little is known about the effect of 
co-trimoxazole resistance when this drug is used for 
prophylaxis rather than treatment, but might be of 
concern if it is ineffective against standard bacterial 
pathogens.32 Giving co-trimoxazole at the recommended 
doses is thought to result in low concentrations in up to a 
third of children,33 which might have altered efficacy in 
our study. Lastly, adherence might have affected the 
efficacy of co-trimoxazole, although we found no 
significant difference between groups in mortality in the 
exploratory as-treated or the intention-to treat analyses, 
which suggests that adherence was not the primary 
explanation for our findings.
Given the low mortality in our placebo group, the 
95% CI for the absolute difference in mortality between 
groups was wide. In previous studies in Africa16–19 
including in Botswana,34 mortality was higher among 
HEU children than among those not exposed to HIV, 
particularly among those fed with formula.25,35 We 
estimated that mortality would be 5·2% between random 
assignment of treatment and age 18 months in the 
placebo group, based on a previous clinical trial at the 
same study sites,25 but this value was double that in our 
findings. The lower mortality we found might have been 
due to improvements in clinical care and in vaccination 
coverage over time, improved maternal health owing to 
widespread ART availability, or improved safety of 
feeding and preparation of formula. The Prevnar and 
rotavirus vaccines were introduced in Botswana during 
the study period, in mid-2012, and might have lowered 
mortality from respiratory and diarrhoeal diseases.36–39 
HIV infection Death or HIV infection* Estimated proportions at age 18 months 
for death and HIV infection (95% CI)
Formula fed only 3 of 2276 56 of 2276 3·0% (2·1–4·0)
Breastfed only†
6 months 1 of 280 9 of 280 3·9% (1·3–6·4)
12 months 1 of 289 4 of 289 1·9% (0·01–3·7)
*No deaths were in children with HIV infection. †Excludes three children who were breastfed but not randomly assigned 
to a feeding duration.
Table 3: Frequency of death and HIV infection, by feeding method
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Mortality might also have been lower than anticipated 
because we excluded children who were thought unlikely 
to survive to age 18 months and those who died before 
age 34 days. Of note, 33 (1%) enrolled neonates died 
before random treatment assignment. Finally, mortality 
could be lower among children participating in a clinical 
trial than among those in a programmatic setting. 
Despite low mortality, our better-powered comparison of 
the composite outcome of death, admission to hospital, 
and grade 3–4 clinical adverse events also did not reveal a 
difference between treatment groups.
This study yielded new safety data for co-trimoxazole 
used in early life. No increase was seen in the frequency of 
grade 3–4 anaemia compared with placebo even with use 
from as early as age 14 days. WHO and other guidelines 
suggest starting co-trimoxazole prophylaxis at age 
4–6 weeks, partly because of the risk of kernicterus with 
sulfafurazole use in preterm neonates.40 We did not see 
this complication among the babies treated from age 
14 days in this study, all of whom were born at full term 
and weighed 2500 g or greater when co-trimoxazole was 
started. Significantly more children had grade 3–4 
neutropenia in the co-trimoxazole than in the placebo 
group, although the absolute difference was small and we 
saw no clinical consequences. Few data exist regarding the 
implications of medication-induced neutropenia for child 
health outcomes in Africa, and the normal ranges for 
neutrophil counts in African children might be lower than 
in the Division of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events.41–44 Lastly, we detected 
an increase in co-trimoxazole resistance among 
commensal E coli stool isolates in the co-trimoxazole 
group; the clinical consequences of this finding are 
unknown.
Our study had several limitations. First, mortality was 
lower than expected. The study was originally powered to 
detect a difference between groups of 40% or more. 
Despite the low mortality, we had power to detect a 50% or 
greater difference in mortality (which amounted to a small 
but clinically meaningful absolute difference in mortality 
between co-trimoxazole vs placebo: 95% CI –1·5% to 1·0%). 
The absence of a difference in the composite outcome of 
death, hospital admission, and grade 3–4 clinical adverse 
events (for which the study was well powered) supports 
the absence of a clinically meaningful effect of co-
trimoxazole. Second, following changes to WHO 
guidelines in 2010,45 and the reporting of data on the safety 
of breastfeeding in the setting of ART prophylaxis in 
Botswana,46 we anticipated that a higher percentage of 
women in our study would opt to breastfeed. However, 
with only 20% choosing breastfeeding instead of the 
estimated 80%, secondary random assignment to a 
6-month or 12-month breastfeeding duration was 
underpowered to show any benefit from longer-term 
breastfeeding. We did, however, note some challenges in 
maintaining longer breast feeding in Botswana. 44% of all 
women approached were enrolled in the study. 
The reasons for refusal (figure 1) suggest little risk of bias 
regarding study entry, with few refusals being due to 
neonatal illness. Nevertheless, we cannot rule out the 
possibility that mothers of the sickest infants were not 
available to be invited to participate. Lastly, the DSMB 
stopped the study early based on the predefined stopping 
guidelines, which led to 39% of children per group having 
data censored before age 18 months.
Extended co-trimoxazole prophylaxis provided no 
survival benefit in HEU children in southern Botswana 
up to age 18 months. Despite being generally well 
tolerated, long-term use of co-trimoxazole in HEU 
children at low risk of late mother-to-child transmission 
of HIV added cost and complexity to care, increased 
antimicrobial resistance, and was associated with slightly 
increased risk of neutropenia. Thus, in non-malarial 
regions with low risk of HIV infection through mother-
to-child transmission, long-term co-trimoxazole 
prophylaxis for HEU children might not be needed.
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